![]() ![]() Studies are underway to gauge efficacy and safety in children aged 0–11 (KidCOVE) and 12–17 (TeenCOVE). Only individuals aged 18 or older were studied. Įfficacy estimates were similar across age groups, sexes, racial and ethnic groups, and participants with medical comorbidities associated with high risk of severe COVID‑19. This efficacy has been described as "astonishing" and "borderline historic" for a respiratory virus vaccine, and it is similar to the efficacy of the Pfizer–BioNTech COVID-19 vaccine. ![]() Moreover, there were zero cases of severe COVID‑19 in the vaccine group, versus eleven in the placebo group. High efficacy is achieved with full immunization, two weeks after the second dose, and was evaluated at 94.1%: at the end of the vaccine study that led to emergency authorization in the US, there were eleven cases of COVID‑19 in the vaccine group (out of 15,181 people) versus 185 cases in the placebo group (15,170 people). Efficacy Cumulative Incidence Curves for the First COVID‑19 Occurrence (Moderna mRNA-1273 vaccine)Įvidence of vaccine efficacy starts about two weeks after the first dose. Ī third, fourth, or fifth dose can be added in some countries. The World Health Organization (WHO) recommends an interval of eight weeks between doses. The initial course consists of two doses. The vaccine is given by intramuscular injection into the deltoid muscle of the arm. The Moderna COVID‑19 vaccine is used to provide protection against infection by the SARS‑CoV‑2 virus in order to prevent COVID‑19. The second component of the version of the bivalent vaccine used in the United States (mRNA-1273.222 ) is based on the Omicron BA.4/BA.5 variant, while the second component in the bivalent vaccine version used in other countries (mRNA-1273.214) is based on the Omicron BA.1 variant. In August and September 2022, bivalent versions of the vaccine (Moderna COVID-19 Vaccine, Bivalent) containing elasomeran/elasomeran 0-omicron (Spikevax Bivalent Zero/Omicron) were authorized for use as booster doses in individuals aged 18 years of age or older in the United Kingdom, Switzerland, Australia, Canada, the European Union, and the United States. It is authorized for use at some level in many countries. It is an mRNA vaccine composed of nucleoside-modified mRNA (modRNA) encoding a spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. It is designed to be administered as two or three 0.5 mL doses given by intramuscular injection at an interval of at least 28 days apart. It provides protection against COVID-19 which is caused by infection by the SARS-CoV-2 virus. Depending on the jurisdiction, it is authorized for use in people aged six months, twelve years, or eighteen years and older. The Moderna COVID‑19 vaccine ( INN: elasomeran), sold under the brand name Spikevax, is a COVID-19 vaccine developed by American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |